['thromboembolism']
['dabigatran etexilate', 'warfarin']

        Inclusion criteria:

          -  Written informed consent in accordance with International Conference on Harmonization
             (ICH) Good Clinical Practice (GCP) guidelines and local legislation and/or regulations

          -  Confirmed diagnosis of Cerebral Venous or dural sinus thrombosis (CVT), with or
             without intracranial haemorrhage

          -  Completion of anticoagulation therapy for 5-15 days which has been administered until
             randomisation; anticoagulation must include full-dose low molecular weight heparin or
             unfractionated heparin

          -  Eligibility for treatment with an oral anticoagulant

          -  Further inclusion criteria apply

        Exclusion criteria:

          -  Cerebral Venous or dural sinus thrombosis (CVT) associated with central nervous system
             infection or due to head trauma

          -  Planned surgical treatment for CVT

          -  Conditions associated with increased risk of bleeding

          -  History of symptomatic non-traumatic intracranial haemorrhage with risk of recurrence
             according to Investigator judgment

          -  Treatment with an antithrombotic regimen for an indication other than CVT and
             requiring continuation of that treatment for the original diagnosis without change in
             the regimen

          -  Severe renal impairment

          -  Active liver disease

          -  Pregnancy, nursing or planning to become pregnant while in the trial

          -  Further exclusion criteria apply
      